Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas

European Journal of Endocrinology

Volumn 163, Issue 5, 2010, Pages 747-755

  Hemerly, Jefferson Pessoa ^a   Bastos, André Uchimura ^a   Cerutti, Janete M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; ISOCITRATE DEHYDROGENASE; RAS PROTEIN; IDH1 PROTEIN, HUMAN;

ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; EXON; GENE FREQUENCY; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE ALIGNMENT; THYROID ADENOMA; THYROID CARCINOMA; THYROID GLAND; AMINO ACID SEQUENCE; ANIMAL; CATTLE; COMPARATIVE STUDY; DOG; ENZYME ACTIVE SITE; GENETICS; MEDULLARY CARCINOMA; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MOUSE; ONCOCYTOMA; PAPILLARY CARCINOMA; RAT; THYROID TUMOR; TUMOR CELL LINE;

ADENOMA, OXYPHILIC; AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; CATALYTIC DOMAIN; CATTLE; CELL LINE, TUMOR; CONSERVED SEQUENCE; DOGS; EVOLUTION, MOLECULAR; GENETIC VARIATION; HUMANS; ISOCITRATE DEHYDROGENASE; MICE; MOLECULAR SEQUENCE DATA; RATS; SEQUENCE ALIGNMENT; THYROID NEOPLASMS;

EID: 77957835307     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0473     Document Type: Article

References (39)

1. Davies L & Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 2006 295 2164-2167. (doi:10.1001/jama.295.18.2164)
2. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 2003 63 1454-1457. (Pubitemid 36373628)
3. Oler G & Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 2009 115 972-980. (doi:10.1002/cncr.24118)
4. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L & Beck-Peccoz P. BRAF mutations in an Italian cohort of thyroid cancers. Clinical Endocrinology 2004 61 239-243. (doi:10.1111/j.1365-2265.2004.02089.x)
5. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM & Fletcher JA. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000 289 1357-1360. (doi:10.1126/science.289.5483.1357) (Pubitemid 30656054)
6. Freitas BC & Cerutti JM. Genetic markers differentiating follicular thyroid carcinoma from benign lesions. Molecular and Cellular Endocrinology 2010 321 77-85. (doi:10.1016/j.mce.2009.11.008)
7. Nakabashi CC, Guimaraes GS, Michaluart P Jr, Ward LS, Cerutti JM & Maciel RM. The expression of PAX8-PPARgamma rearrangements is not specific to follicular thyroid carcinoma. Clinical Endocrinology 2004 61 280-282. (doi:10.1111/j.1365-2265.2004.02061.x)
8. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF & de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. Journal of Clinical Endocrinology and Metabolism 2003 88 2745-2752. (doi:10.1210/jc.2002-021186)
9. Yeager N, Klein-Szanto A, Kimura S & Di Cristofano A. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Research 2007 67 959-966. (doi:10.1158/0008-5472.CAN-06-3524) (Pubitemid 46270750)
10. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW & Velculescu VE. The consensus coding sequences of human breast and colorectal cancers. Science 2006 314 268-274. (doi:10.1126/science.1133427)
11. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE & Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science 2008 321 1807-1812. (doi:10.1126/science.1164382)
12. Iuliano R, Trapasso F, Stella A, Le Pera I, Melillo RM, Bruni P, Baldassarre G, Chiariotti L, Santoro M, Viglietto G & Fusco A. Pivotal role of the RB family proteins in in vitro thyroid cell transformation. Experimental Cell Research 2000 260 257-267. (doi:10.1006/excr.2000.5023)
13. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH & Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigation 1993 91 179-184. (doi:10.1172/JCI116168)
14. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J & Santoro M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Research 2005 65 10199-10207. (doi:10.1158/0008-5472.CAN-04-4259) (Pubitemid 41743711)
15. Boltze C, Zack S, Quednow C, Bettge S, Roessner A & Schneider-Stock R. Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis. Pathology, Research and Practice 2003 199 399-404. (doi:10.1078/0344-0338-00436) (Pubitemid 36974825)
16. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B & Bigner DD. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine 2009 360 765-773. (doi:10.1056/NEJMoa0808710)
17. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A & Bardelli A. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Human Mutation 2009 30 7-11. (doi:10.1002/humu.20937)
18. Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA & Bloomfield CD. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of Clinical Oncology 2010 28 2348-2355. (doi:10.1200/JCO.2009.27. 3730)
19. Murugan AK, Bojdani E & Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochemical and Biophysical Research Communications 2010 393 555-559. (doi:10.1016/j.bbrc.2010.02.095)
20. Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, Ottmann O, Lubbert M, Heit W, Kanz L, Schlimok G, Raghavachar AA, Fiedler W, Kirchner HH, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A & Krauter J. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. Journal of Clinical Oncology 2010 28 2356-2364. (doi:10.1200/JCO.2009.27.6899)
21. Xu X, Zhao J, Xu Z, Peng B, Huang Q, Arnold E & Ding J. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. Journal of Biological Chemistry 2004 279 33946-33957. (doi:10.1074/jbc.M404298200)
22. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG & Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009 462 739-744. (doi:10.1038/nature08617)
23. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A & Hartmann C. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathologica 2009 118 401-405. (doi:10.1007/s00401-009-0550-z)
24. Oler G, Ebina KN, Michaluart P Jr, Kimura ET & Cerutti J. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clinical Endocrinology 2005 62 509-511. (doi:10.1111/j.1365-2265.2005.02235.x) (Pubitemid 40503381)
25. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK & Ley TJ. Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine 2009 361 1058-1066. (doi:10.1056/NEJMoa0903840)
26. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL & Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009 324 261-265. (doi:10.1126/science.1170944)
27. Frezza C, Tennant DA & Gottlieb E. IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell 2010 17 7-9. (doi:10.1016/j.ccr.2009.12.031)
28. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR & Mak TW. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. Journal of Experimental Medicine 2010 207 339-344. (doi:10.1084/jem.20092506)
29. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL & Thompson CB. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010 17 225-234. (doi:10.1016/j.ccr.2010.01. 020)
30. Varfolomeev SD, Uporov IV & Fedorov EV. Bioinformatics and molecular modeling in chemical enzymology. Active sites of hydrolases. Biochemistry (Moscow) 2002 67 1099-1108. (doi:10.1023/A:1020907122341)
31. Merlo LM, Pepper JW, Reid BJ & Maley CC. Cancer as an evolutionary and ecological process. Nature Reviews. Cancer 2006 6 924-935. (doi:10.1038/nrc2013)
32. Watanabe T, Vital A, Nobusawa S, Kleihues P & Ohgaki H. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathologica 2009 117 653-656. (doi:10.1007/s00401-009-0528- x)
33. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T & Sanson M. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research 2010 16 1597-1604. (doi:10.1158/1078-0432.CCR-09-2902)
34. Cerutti JM, Latini FR, Nakabashi C, Delcelo R, Andrade VP, Amadei MJ, Maciel RM, Hojaij FC, Hollis D, Shoemaker J & Riggins GJ. Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clinical Cancer Research 2006 12 3311-3318. (doi:10.1158/1078-0432.CCR-05-2226)
35. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J & Riggins GJ. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. Journal of Clinical Investigation 2004 113 1234-1242. (doi:10.1172/JCI19617) (Pubitemid 38544109)
36. Cerutti JM. Nodule diagnosed as follicular patterned lesion: are biomarkers the promise? Arquivos Brasileiros de Endocrinologia e Metabologia 2007 51 832-842.
37. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R & Singh B. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Research 2004 64 3780-3789. (doi:10.1158/0008-5472.CAN-03-1460)
38. Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Reaman GH, Baker LH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL & Meshinchi S. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia 2010 24 909-913. (doi:10.1038/leu.2010.56)
39. Knudsen B & Miyamoto MM. Sequence alignments and pair hidden Markov models using evolutionary history. Journal of Molecular Biology 2003 333 453-460. (doi:10.1016/j.jmb.2003.08.015) (Pubitemid 37188584)